On September 11–17, 2026, Ekaterinburg hosted the International Youth Festival, a large-scale event that brought together 10,000 young leaders from 191 countries. At the festival running under the motto «Follow Your Dream,» the Medsintez Plant presented its exhibition, showcasing the achievements of the Ural pharmaceutical industry in the field of import substitution.
The updated clinical guidelines for treatment of ARVI in children took effect on September 2, 2026. The document was developed by leading experts from the Union of Pediatricians of Russia, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and the Russian Society of Emergency Medical Care and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. It fundamentally shifts therapeutic approaches toward enhanced safety and minimal drug burden.
On September 3–4, 2026, Nizhny Novgorod hosted the 2nd Regional Endocrinological Congress: Challenges and Prospects of the Volga Region, with the active participation of the Medsintez Plant. As a strategic company, Medsintez Plant has been ensuring Russia's pharmaceutical security for 25 years. Company's exhibition booth showcased a range of hormonal medications for treatment of type 1 and type 2 diabetes, as well as drugs for infertility treatment through the IVF method.
More than twenty years ago, the Regiony Rossii (Regions of Russia, RR) magazine witnessed the birth of an innovative pharmaceutical production facility in Novouralsk, which had no analogues in the country. Today, the Medsintez Plant is a strategic asset in terms of national pharmaceutical security, a recognized industry leader, a National Champion, and a winner of prestigious awards. The secret behind the success of the Ural school of pharmaceuticals and biotechnology is explored in this article by RR.
Nonprofit Partnership "Ural Biomedical Cluster" was founded in December 2010 as a comprehensive innovative project. Its difference from an industrial cluster is that, in addition to manufacturing facilities, there are research centers, laboratories for preclinical studies, educational structures and clinics successfully operating based on the Cluster.



Strategic goal of the Ural Biomedical Cluster is to form a high-tech complex of interconnected production and infrastructure facilities for development, production and sale of modern medicines, medical equipment and high- quality medical devices in the Urals region.
The global mission of the Ural Biomedical Cluster is a widespread increase in availability of advanced medical technologies in Russia.
Today, the Ural Biomedical Cluster includes over 30 companies.
Ural Biomedical Cluster Services:

Intellectual Property
Management Patent search, detection of patented technologies, patent landscape designing, intellectual property protection, legal support.

Project Management
Development and execution of a registration dossier, support, business planning, investor search, strategic planning.

Technology Transfer
Development and scaling of original formulations for pharmaceutical products and drugs, existing technologies transfer to a specific site (localization of production).

Human Resources
Personnel training upon request: master's degree, residency, advanced training courses, internships at the enterprises of the Cluster and partners.

Contract Manufacturing
Manufacturing of pharmaceutical products and medical devices to order.

Related Services
Provision of office, laboratory and production premises, logistics services.
Articles of Association dated 24/9/2012